Can I Ever Be Cured? Strategies for Remission of Type 2 Diabetes

Keck School of Medicine of USC

R. Retnakaran

Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

Functional Hypothalamic Amenorrhea: Consequences Beyond the Menstrua…

Heart in Diabetes (HiD)

C. Shufelt

Cardiovascular Disease in the Very Old

Heart in Diabetes (HiD)

C. Ballantyne

Obesity in the Year 2024

Barbara Mcgowan

What Are the Metabolic Consequences of Insulin Resistance and What I…

Penn Medicine Heart and Vascular Center

D. Soffer

Glucagon-like Peptide-1 Receptor Agonist-Based Agents and Weight Los…

Robert Dubin

What’s New in Obesity Pharmacotherapy?

National Lipid Association

H. Bays

Getting Your Cholesterol to Goal: The Growing List of Therapies

The North American Thrombosis Forum (NATF)

N. Marston

Update on GLP1 RA and SGLT2 Inhibitors in HFpEF

MUSC Cardiology

M. Kosiborod

New Targets and Upcoming Medications for Dyslipidemia

Heart in Diabetes (HiD)

N. E. Lepor

Who Is Appropriate for PCSK-9 Inhibitors, Including Inclisiran?

Penn Medicine Heart and Vascular Center

A. Bajaj

GLP’s Are Anti-Consumption and Longevity Agents and SGLT-i’s Slow Ag…

James O'Keefe

Eradicating Atherosclerotic Events by Targeting Early Subclinical Di…

Heart in Diabetes (HiD)

K. Jon Williams

Heart Failure Post Myocardial Infraction and Valvular Disease

Heart in Diabetes (HiD)

J. Butler

Impact of Cumulative Risk Factor Exposure on Incident Cardiovascular…

Heart in Diabetes (HiD)

M. J. Domanski

Should I Use a Continuous Glucose Monitor, Even if I'm Healthy?

Integrative Medicine - Astrid Pujari

A. Pujari

The PCSK9 - From Discovery to Translation & the Future of Therapeuti…

University of Louisville

M. Shapiro

CAC Scoring in Assessment of Cardiovascular Risk

University Hospitals

G. Rao, I. Neeland

Best Practices for Treating Cardio-Renal-Metabolic Disease

Primary Care Education Consortium

L. Novak, L. Foster Smith